Abstracts tagged "Sjogren’s syndrome and anti-centromere antibodies (ACA)"

Abstract Number: 2427 • 2019 ACR/ARP Annual Meeting
The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjogren’s Syndrome : Data from a Prospective Korean Nation-wide Cohort
Youngjae Park¹, Jennifer Lee ¹, Jung Hee Koh ², Jung Yoon Choe ³, Yoon-Kyoung Sung ⁴, Shin-Seok Lee ⁵, Ji-Min Kim ⁶, Wan-Uk Kim ¹, Sung-Hwan Park ¹ and Seung-Ki Kwok ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Bucheon, Republic of Korea, ³Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Centre, Daegu, Republic of Korea
Background/Purpose: To clarify clinical features of primary Sjogren’s syndrome (SS) patients who show the positivity for anti-centromere antibody in Korea.Methods: We assessed 318 patients who…
Abstract Number: 575 • 2017 ACR/ARHP Annual Meeting
Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study
Masako Tsukamoto^1,2, Katsuya Suzuki¹, Noriyuki Seta² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan
Background/Purpose: Anti-centromere antibody (ACA) positive Sjögren’s syndrome (SS) is considered as a subtype in SS. Recent international collaborative large scale cohort study highlighted several clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].